Holen Sie sich die Stockscreener-App
120.02
0.37%
-0.45
Vorhandelsmarkt:
120.08
0.06
+0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$120.47
Offen:
$120.56
24-Stunden-Volumen:
6.08M
Relative Volume:
0.80
Marktkapitalisierung:
$148.92B
Einnahmen:
$28.86B
Nettoeinkommen (Verlust:
$6.31B
KGV:
23.91
EPS:
5.02
Netto-Cashflow:
$9.37B
1W Leistung:
+6.72%
1M Leistung:
+9.47%
6M Leistung:
+16.17%
1J Leistung:
+64.43%
1-Tages-Spanne:
$119.26
$121.83
1-Wochen-Bereich:
$108.54
$121.83
52-Wochen-Spanne:
$72.67
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
120.02 | 149.48B | 28.86B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
639.43 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.64 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
119.31 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.30 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences stock hits 52-week high at 121.67 USD By Investing.com - Investing.com South Africa
Gilead Sciences stock hits 52-week high at 121.67 USD - Investing.com
Gilead Sciences: Strong Q2 Performance and Promising Yeztugo Launch Support Buy Rating - TipRanks
Stock Analysis | Gilead Sciences OutlookA Mixed Picture Amid Volatile Technicals - AInvest
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus - TradingView
Gilead Sciences’ Earnings Call Highlights Growth and Strategic Advances - TipRanks
Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir - Insider Monkey
Gilead Sciences Explores New Dosing for Triple-Negative Breast Cancer Treatment - TipRanks
Gilead Sciences’ Phase 3 Study on Sacituzumab Govitecan: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Deutsche Bank Adjusts Gilead Sciences Price Target to $135 From $120, Maintains Buy Rating - MarketScreener
Kymera Revenue Drops 55 Percent in Q2 - The Motley Fool
Factory fallout: Manufacturing plant closures and layoffs from Dow, Gilead Sciences, Whitford, and more - Plant Services
Gilead drops Novo Nordisk-partnered liver disease candidate - medwatch.com
Gilead Sciences soars on strong HIV drug sales - medwatch.com
Gilead Sciences (GILD) Is Up 5.5% After Earnings Beat and EU Lenacapavir Milestone – What's Changed - simplywall.st
Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside. - MSN
Gilead Stock Is Closing In on an All-Time High. The Case for More Upside. - Barron's
Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating - TipRanks
Gilead Sciences’ Twice-Yearly HIV Prevention Drug Recommended for Approval by European Medicines Agency - Insider Monkey
Gilead Sciences Inc. Recovery Hinges on Volume BreakoutRisk Adjusted Technical Entry Plan Gains Followers - beatles.ru
Gilead Sciences' Strategic Momentum with Yeztugo and HIV Portfolio Growth: A Cornerstone for Long-Term Value Creation - AInvest
Gilead Sciences: A Resilient HIV Franchise and Strategic Catalysts for Long-Term Growth - AInvest
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish - MSN
The Gilead Sciences, Inc. (NASDAQ:GILD) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences (GILD) Rises on Raised 2025 Guidance and $6B Buyback Is Its Outlook Reinvigorated? - simplywall.st
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details here - MSN
Gilead trims assets partnered with Novo Nordisk, Arcus from pipeline - firstwordpharma.com
Gilead Sciences Surges 8.28% On Bullish Breakout With Heavy Volume - AInvest
Earnings Season Boosts Confidence: Gilead and Expedia Lead Strong Corporate Results - FinancialContent
These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More - Barron's
Gilead Surges 8%, Flirting With A Breakout, On Growing Enthusiasm For HIV PrEP - Investor's Business Daily
Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook - Invezz
Gilead Rallies: Bullish Surge Continues! - timothysykes.com
Gilead Sciences stock price target raised to $140 from $126 at BofA - Investing.com
NASDAQ Index, SP500, Dow Jones Forecasts – NASDAQ Gains Ground As Gilead Sciences Soars 8% - FXEmpire
Gilead Sciences jumps after Q2 beat; Truist upgrades to Buy - MSN
Gilead Sciences’ Yeztugo Projected to Reach $5 Billion in Global Sales by 2031 - geneonline.com
Earnings Season Highlights: Gilead Sciences and Expedia Group Post Strong Results - FinancialContent
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details - The Economic Times
Gilead’s Yeztugo sales “ahead of expectations” following launch - Yahoo Finance
Gilead Sciences’ Breast Cancer Study: A Potential Game-Changer in Oncology? - TipRanks
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today - Yahoo Finance
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Gilead Sciences Stock Surges 9% on Strong Q2 Earnings - AInvest
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
Gilead culls Novo-partnered MASH candidate and 2 cancer assets - Fierce Biotech
Amid excitement over Yeztugo, Gilead sees continued erosion of CAR-T sales - Fierce Pharma
Gilead Sciences Up Over 8%, on Track for Highest Close Since June 2015 — Data Talk - Morningstar
Why Is Gilead Sciences Stock Surging Friday?Gilead Sciences (NASDAQ:GILD) - Benzinga
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):